[Treatment of prostatic adenoma].
We used lymphotropic therapy in addition to standard treatment in 116 of 232 patients with benign prostatic hyperplasia. The effect was evaluated in the course of treatment and followed up for a year. Improvement in general condition of the patients, symptoms of infravesical obstruction, size of the prostate, urinary flow rate demonstrated high efficacy of lymphotropic therapy leading to a higher rate of persistent remission and higher quality of life.
V B
VB
Borisov
D058891:5-alpha Reductase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000276:Adjuvants, Immunologic / Q000008:administration & dosage / Q000627:therapeutic use; D058668:Adrenergic alpha-1 Receptor Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D018120:Finasteride / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D006821:Hyaluronoglucosaminidase / Q000008:administration & dosage / Q000627:therapeutic use; D007272:Injections, Intralymphatic; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology; D011472:Prostatitis / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology; D013449:Sulfonamides / Q000008:administration & dosage / Q000627:therapeutic use*; D000077409:Tamsulosin; D016896:Treatment Outcome
D058891:5-alpha Reductase Inhibitors; D000276:Adjuvants, Immunologic; D058668:Adrenergic alpha-1 Receptor Antagonists; D000900:Anti-Bacterial Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D013449:Sulfonamides; D018120:Finasteride; C001543:lidase; D006821:Hyaluronoglucosaminidase; D000077409:Tamsulosin